Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret)

被引:38
作者
Wang, Yutao [1 ]
Ding, Yuewen [1 ,2 ]
Yang, Chunguang [1 ]
Li, Runfeng [1 ]
Du, Qiuling [1 ]
Hao, Yanbing [1 ]
Li, Zhengtu [1 ]
Jiang, Haiming [1 ]
Zhao, Jin [1 ]
Chen, Qiaoyan [1 ,3 ]
Yang, Zifeng [1 ,4 ]
He, Zhanlong [5 ]
机构
[1] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis, Guangzhou 510120, Guangdong, Peoples R China
[2] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China
[3] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Clin Coll 2, Guangzhou 510006, Guangdong, Peoples R China
[4] Macau Univ Sci & Technol, Fac Chinese Med, Taipa, Macao, Peoples R China
[5] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China
基金
中国国家自然科学基金;
关键词
Arbidol hydrochloride; Influenza virus; Anti-viral; Anti-inflammatory; ANTIVIRAL DRUG ARBIDOL; A H1N1 VIRUS; PATHOGENESIS; DERIVATIVES;
D O I
10.1016/j.biopha.2017.04.091
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Influenza virus infections are the main contagious respiratory disease with high levels of morbidity and mortality worldwide. Antiviral drugs are indispensable for the prophylaxis and treatment of influenza and other respiratory viral infections. In this study, the Arbidol hydrochloride (ARB), which has been licensed in Russia and China, is used to investigate its anti-viral and anti-inflammatory efficacy in vitro and in vivo. The antiviral results in vitro showed that ARB had a better inhibition on Influenza virus A/PR/8/34 (H1N1), A/Guangdong/GIRD07/09 (H1N1), A/Aichi/2/68 (H3N2), A/HK/Y280/97 (H9N2) with IC50 ranging from 4.4 to 12.1 mu M. The further mechanisms study demonstrated that ARB is able to inhibit hemagglutinin-mediated hemolysis at concentration of 3.91-15.63 mu g/mL. The anti-inflammatory efficacy in vitro indicated that IL-6, IP-10, MCP-1, RANTES and TNF-alpha levels were diminished by ARB at concentrations of 22.6 and 18.8 mu M. The in vivo results in mice model displayed that the survival rates of mice administered 25 mg/mL and 45 mg/mL ARB were 40% and 50% respectively. And also, ARB can inhibit the decrease of body weight at 45 mg/mL and inhibit the increase of mice lung index at 25 mg/mL and 45 mg/mL comparing to virus group. In ferret model, the ARB-treated ferrets showed a fever that peaked at 2 dpi and gradually decreased beginning at 3 dpi while relatively high temperatures were observed until 4 dpi in the virus group. The ARB-treated group scored 0-1 in the activity level at 2 dpi and 3 dpi at all time points. The transcription levels of cytokines in the respiratory tract of ferrets were detected at 3 dpi. Several proinflammatory cytokines induced by influenza (IL-10, TNF-alpha, IL-8 and IL-6) were down-regulated by post-treatment with ARB. The histopathological results of ferret lung displayed that ARB can alleviate the influenza virus induced lung lesions. Our results clarified the activity of ARB in both suppressing virus propagation and modulating the expression of inflammatory cytokines in vitro and in vivo, it can be as an effective drug to treat the influenza virus infection. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:393 / 401
页数:9
相关论文
共 36 条
  • [1] Animal models for the study of influenza pathogenesis and therapy
    Barnard, Dale L.
    [J]. ANTIVIRAL RESEARCH, 2009, 82 (02) : A110 - A120
  • [2] Arbidol as a broad-spectrum antiviral: An update
    Blaising, Julie
    Polyak, Stephen J.
    Pecheur, Eve-Isabelle
    [J]. ANTIVIRAL RESEARCH, 2014, 107 : 84 - 94
  • [3] Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking
    Blaising, Julie
    Levy, Pierre L.
    Polyak, Stephen J.
    Stanifer, Megan
    Boulant, Steeve
    Pecheur, Eve-Isabelle
    [J]. ANTIVIRAL RESEARCH, 2013, 100 (01) : 215 - 219
  • [4] Antiviral Activity of Arbidol, a Broad-Spectrum Drug for Use Against Respiratory Viruses, Varies According to Test Conditions
    Brooks, Megan J.
    Burtseva, Elena I.
    Ellery, Philip J.
    Marsh, Glenn A.
    Lew, Andrew M.
    Slepushkin, Anatoly N.
    Crowe, Suzanne M.
    Tannock, Gregory A.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (01) : 170 - 181
  • [5] Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team
    Dawood, Fatimah S.
    Jain, Seema
    Finelli, Lyn
    Shaw, Michael W.
    Lindstrom, Stephen
    Garten, Rebecca J.
    Gubareva, Larisa V.
    Xu, Xiyan
    Bridges, Carolyn B.
    Uyeki, Timothy M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (25) : 2605 - 2615
  • [6] Antiviral agents active against influenza A viruses
    De Clercq, Erik
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (12) : 1015 - 1025
  • [7] Efficacy of arbidol on lethal hantaan virus infections in suckling mice and in vitro
    Deng, Hai-ying
    Luo, Fan
    Shi, Li-qiao
    Zhong, Qiong
    Liu, Ying-juan
    Yang, Zhan-qiu
    [J]. ACTA PHARMACOLOGICA SINICA, 2009, 30 (07) : 1015 - 1024
  • [8] Structure-activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication
    Di Mola, Antonia
    Peduto, Antonella
    La Gatta, Annalisa
    Delang, Leen
    Pastorino, Boris
    Neyts, Johan
    Leyssen, Pieter
    de Rosa, Mario
    Filosa, Rosanna
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (21) : 6014 - 6025
  • [9] Antiviral combinations for severe influenza
    Dunning, Jake
    Baillie, J. Kenneth
    Cao, Bin
    Hayden, Frederick G.
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (12) : 1259 - 1270
  • [10] Fiore AE, 2009, CURR TOP MICROBIOL, V333, P43, DOI 10.1007/978-3-540-92165-3_3